Xilio Therapeutics, Inc. XLO
We take great care to ensure that the data presented and summarized in this overview for Xilio Therapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding XLO
View all-
Bain Capital Life Sciences Investors, LLC Boston, MA4.57MShares$3.43 Million1.18% of portfolio
-
Rock Springs Capital Management LP Baltimore, MD3MShares$2.25 Million0.12% of portfolio
-
River Vest Venture Management LLC St. Louis, MO1.44MShares$1.08 Million16.6% of portfolio
-
Morgan Stanley New York, NY1MShares$751,0190.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA903KShares$676,8980.0% of portfolio
-
Aju Ib Investment Co., Ltd. Seoul, M5668KShares$500,8060.57% of portfolio
-
Geode Capital Management, LLC Boston, MA358KShares$268,8160.0% of portfolio
-
Balyasny Asset Management LLC Chicago, IL343KShares$257,4220.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny297KShares$222,4620.0% of portfolio
-
Trustees Of Columbia University In The City Of New York New York, NY250KShares$187,2260.04% of portfolio
Latest Institutional Activity in XLO
Top Purchases
Top Sells
About XLO
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies to improve the immune system of cancer patients. Its checkpoint inhibitor program includes XTX101, a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Phase 1/2 clinical trials in patients with solid tumors. The company also develops cytokine programs, which comprises XTX202, a modified form of IL-2; XTX301, an IL-12 product candidate; and XTX401, an IL-15 product candidate that are masked with a protein domain to prevent binding activity until cleaved off by tumor microenvironment (TME)-associated proteases. Xilio Therapeutics, Inc. was founded in 2016 and is headquartered in Waltham, Massachusetts.
Insider Transactions at XLO
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|
Jan 02
2025
|
Kevin M. Brennan SVP, FINANCE AND ACCOUNTING |
SELL
Open market or private sale
|
Direct |
1,803
-36.06%
|
$0
$0.98 P/Share
|
|
Jan 02
2025
|
Christopher James Frankenfield Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
6,954
-35.89%
|
$0
$0.98 P/Share
|
|
Jan 01
2025
|
Rene Russo PRESIDENT AND CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
44,250
+15.3%
|
-
|
|
Jan 01
2025
|
Kevin M. Brennan SVP, FINANCE AND ACCOUNTING |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+50.0%
|
-
|
|
Jan 01
2025
|
Christopher James Frankenfield Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
19,375
+50.0%
|
-
|
|
Jan 01
2025
|
Katarina Luptakova CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
16,625
+50.0%
|
-
|
|
Dec 18
2024
|
Gilead Sciences Inc > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
1,759,978
+16.2%
|
$1,759,978
$1.04 P/Share
|
|
Apr 02
2024
|
Gilead Sciences Inc > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
485,250
+6.2%
|
$0
$0.76 P/Share
|
|
Feb 08
2024
|
Atlas Venture Fund Xi, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
267
-0.04%
|
$0
$0.64 P/Share
|
|
Feb 08
2024
|
Atlas Venture Fund Xi, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
733
-0.04%
|
$0
$0.64 P/Share
|
|
Jan 12
2024
|
Atlas Venture Fund Xi, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
560
-0.08%
|
$0
$0.83 P/Share
|
|
Jan 12
2024
|
Atlas Venture Fund Xi, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
1,540
-0.08%
|
$0
$0.83 P/Share
|
|
Jan 11
2024
|
Atlas Venture Fund Xi, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
569
-0.08%
|
$0
$0.87 P/Share
|
|
Jan 11
2024
|
Atlas Venture Fund Xi, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
1,566
-0.08%
|
$0
$0.87 P/Share
|
|
Dec 10
2021
|
Bain Capital Life Sciences Investors, LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
25,000
+0.44%
|
$225,000
$9.9 P/Share
|
|
Dec 09
2021
|
Bain Capital Life Sciences Investors, LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
4,011
+0.14%
|
$36,099
$9.84 P/Share
|
|
Dec 08
2021
|
Bain Capital Life Sciences Investors, LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
13,458
+0.48%
|
$121,122
$9.62 P/Share
|
|
Oct 26
2021
|
Sv7 Impact Medicine Fund LP > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
1,301,132
+34.43%
|
-
|
|
Oct 26
2021
|
Sv7 Impact Medicine Fund LP > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
1,301,132
+34.43%
|
-
|
|
Oct 26
2021
|
Fmr LLC |
BUY
Conversion of derivative security
|
Indirect |
1,881,355
+36.48%
|
-
|
Last 12 Months Summary
| Open market or private purchase | 1.76M shares |
|---|---|
| Exercise of conversion of derivative security | 85.3K shares |
| Open market or private sale | 8.76K shares |
|---|